Leveraging FDA Expedited Pathways to Accelerate Product Development

Dec 09, 2019

Posted by Veristat, LLC

BioIVT to Host Drug Discovery Webinar on Gene Silencing Using siRNA In Hepatocyte Co-cultures

Dec 09, 2019

Posted by BioIVT

HalioDx and Kite, a Gilead company, to extend strategic collaboration beyond Lymphoma

Dec 06, 2019

Optimizing Successful Development of Viral Vector Gene Therapies, Gene Therapy Trials, and Companion Diagnostics

Dec 05, 2019

Free Energy Perturbation (FEP): Another technique in the drug discovery toolbox

Dec 05, 2019

Posted by Cresset

Aiforia Introduces Velocity

Dec 04, 2019

Cresset Discovery Services contracted by PhoreMost to work on ‘undruggable’ oncology protein target

Dec 04, 2019

Posted by Cresset

The Role of Integrated Scientific Advice for the Early Determination of RWE Requirements in HTA and Payer Assessments

Dec 03, 2019

Faster time to clinical candidate using FEP activity prediction now universally available in Flare™ V3

Dec 03, 2019

Posted by Cresset

Perspectives on Gene Therapy: Defining and Demonstrating Value to Payers

Nov 27, 2019

Flare™ V3 release features fully validated and accessible FEP calculations and new workflows

Nov 26, 2019

Posted by Cresset